Axmed, a Swiss HealthTech firm, at this time introduced it has been awarded €5 million ($6 million) in non-dilutive grant funding from the Gates Basis to develop entry to high-quality, inexpensive medicines throughout low- and middle-income international locations by means of its B2B procurement and built-in logistics platform.
The grant builds on the Basis’s prior €4.2 million ($5 million). With further backing from Founderful Ventures, the corporate has now raised a complete of €11 million ($13 million) in capital so far.
“This funding permits us to scale what already works whereas we herald aligned long-term capital,” says Emmanuel Akpakwu, Founder and CEO of Axmed. “With the continued help of the Gates Basis, our focus is disciplined execution at scale: strengthening procurement methods, enhancing affordability, and making certain high-quality medicines reliably attain the individuals who rely upon them.”
Within the broader 2025–2026 HealthTech panorama, a number of adjoining rounds illustrate continued capital circulate into healthcare supply and digital infrastructure.
Germany’s Qrago (Stuttgart) secured €2.7 million to digitise healthcare logistics and transport operations, whereas UK-based Wanda Health raised €2.1 million to scale its clever digital care platform aimed toward decreasing hospital readmissions.
At a bigger ticket measurement, UK ladies’s well being platform SheMed closed a €43 million spherical to develop personalised preventative healthcare providers.
Collectively, these rounds quantity to roughly €47.8 million in disclosed funding throughout digital well being and healthcare operations segments.
Inside this 2025–2026 cohort, capital deployment displays investor curiosity in enhancing healthcare system effectivity, whether or not by means of logistics digitisation, digital care, or specialised service platforms, situating Axmed’s grant inside a wider pattern of infrastructure-oriented HealthTech funding.
“Though Axmed is a younger organisation, their mannequin of leveraging a technology-enabled market to enhance entry to important medicines in rising markets is each progressive and important,” provides Denise Tuiime Mutambi, Director of Planning and Procurement at Joint Medical Shops. “They’ve demonstrated an distinctive capacity to navigate world healthcare provide chain complexity and translate technique into measurable and sustainable impression.”
Based in 2023, Axmed is a technology-enabled B2B market and logistics platform that connects consumers, producers, and distributors to streamline procurement and supply of important medicines throughout low- and middle-income international locations.
By combining pooled demand, data-driven sourcing, and built-in worldwide logistics, Axmed reduces prices, will increase provide reliability, and expands affected person entry to quality-assured healthcare merchandise.
The corporate additionally counts with regional headquarters in Nairobi, Kenya.
The brand new funding will speed up Axmed’s enlargement throughout Africa and help procurement programmes spanning a number of therapeutic areas, together with household planning and malaria merchandise serving moms, kids, and underserved affected person populations throughout LMICs over the following 12 to 18 months.
Since launch, Axmed has developed a geo-agnostic pooled procurement and logistics platform purpose-built for fragmented and supply-constrained healthcare markets. In 2025 alone, the platform delivered greater than 1,800 metric tonnes of healthcare merchandise and reached over 4.2 million sufferers, up from roughly 750,000 in 2024. Over the identical interval, Axmed recorded 12x year-on-year income development and maintained a mean 70% repeat buy price.
By means of demand aggregation, value transparency, and coordinated worldwide logistics, the platform reportedly generates 30 to 35% value financial savings for patrons.
Axmed plans to function in additional than 20 international locations by the tip of 2026, with a goal of reaching 50 million sufferers inside three years and over 100 million inside 5 years, positioning the platform as a core infrastructure layer for medicines procurement in underserved markets.
